Citations (83)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Didier Cataldo, Renaud Louis, Alain Michils, Rudi Peché, Charles Pilette, Florence Schleich, Vincent Ninane & Shane Hanon. (2021) Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways. Journal of Asthma 58:4, pages 448-458.
Read now
Read now
Kenneth M. Faulkner, Karen MacDonald, Ivo Abraham, Abdulaziz Alhossan & Christopher S. Lee. (2021) ‘Real-world’ effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis. Expert Review of Clinical Immunology 17:1, pages 73-83.
Read now
Read now
Giorgio Walter Canonica, Giorgio Lorenzo Colombo, Paola Rogliani, Pierachille Santus, Claudia Pitotti, Sergio Di Matteo, Chiara Martinotti & Giacomo Matteo Bruno. (2020) Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study. Risk Management and Healthcare Policy 13, pages 43-53.
Read now
Read now
Jason K Lee, Suvina Amin, Michelle Erdmann, Atif Kukaswadia, Jelena Ivanovic, Aren Fischer & Alain Gendron. (2020) Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada. Patient Preference and Adherence 14, pages 725-735.
Read now
Read now
Karen M. MacDonald, Abhishek Kavati, Benjamin Ortiz, Abdulaziz Alhossan, Christopher S. Lee & Ivo Abraham. (2019) Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert Review of Clinical Immunology 15:5, pages 553-569.
Read now
Read now
Cristoforo Incorvaia, Marina Mauro, Elena Makri, Gualtiero Leo & Erminia Ridolo. (2018) Two decades with omalizumab: what we still have to learn. Biologics: Targets and Therapy 12, pages 135-142.
Read now
Read now
Zeynep Çelebi Sözener, Ömür Aydın, Zeynep Mısırlıgil, Dilşad Mungan, Yavuz Selim Demirel, Gülfem E. Çelik, Betül A. Sin & Sevim Bavbek. (2018) Omalizumab in non-allergic Asthma: A report of 13 cases. Journal of Asthma 55:7, pages 756-763.
Read now
Read now
Howraman Meteran, Hanieh Meteran, Celeste Porsbjerg & Vibeke Backer. (2017) Novel monoclonal treatments in severe asthma. Journal of Asthma 54:10, pages 991-1011.
Read now
Read now
Jean Bousquet. (2017) LETTER TO THE EDITOR. European Clinical Respiratory Journal 4:1.
Read now
Read now
Ching-Hsiung Lin & Shih-Lung Cheng. (2016) A review of omalizumab for the management of severe asthma. Drug Design, Development and Therapy 10, pages 2369-2378.
Read now
Read now
Maxime Luu, Marc Bardou, Philippe Bonniaud & Françoise Goirand. (2016) Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma. Expert Opinion on Drug Metabolism & Toxicology 12:12, pages 1503-1511.
Read now
Read now
Alberto Nahon Levy, Antonio J. García a Ruiz, Nuria García-Agua Soler & María Victoria Hidalgo Sanjuan. (2015) Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective. Journal of Asthma 52:2, pages 205-210.
Read now
Read now
Cristoforo Incorvaia, Marina Mauro, Marina Russello, Chiara Formigoni, Gian Galeazzo Riario-Sforza & Erminia Ridolo. (2014) Omalizumab, an anti-immunoglobulin E antibody: state of the art. Drug Design, Development and Therapy 8, pages 197-207.
Read now
Read now
Adel H. Mansur, Lisa Afridi, Julie Sullivan, Jon G. Ayres & Duncan Wilson. (2014) Continuous terbutaline infusion in severe asthma in adults: a retrospective study of long-term efficacy and safety. Journal of Asthma 51:10, pages 1076-1082.
Read now
Read now
Articles from other publishers (69)
V. V. Naumova, E. K. Beltyukov, D. V. Kiseleva, A. A. Shtanova & D. A. Stepina. (2023) Omalizumab: a quarter of a century in the fight against T2-inflammatory diseases of upper and lower respiratory tract. Meditsinskiy sovet = Medical Council:20, pages 68-83.
Crossref
Crossref
Saeed Pirmoradi, Seyed Mahdi Hosseiniyan Khatibi, Sepideh Zununi Vahed, Hamed Homaei Rad, Amir Mahdi Khamaneh, Zahra Akbarpour, Ensiyeh Seyedrezazadeh, Mohammad Teshnehlab, Kenneth R. Chapman & Khalil Ansarin. (2023) Unraveling the link between PTBP1 and severe asthma through machine learning and association rule mining method. Scientific Reports 13:1.
Crossref
Crossref
Christian Domingo, Rosa M. Mirapeix, Francisco-Javier González-Barcala, Carles Forné & Felip García. (2023) Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study. Drugs 83:12, pages 1111-1123.
Crossref
Crossref
Francisco Javier Alvarez-Gutiérrez, Marina Blanco-Aparicio, Francisco Casas-Maldonado, Vicente Plaza, Francisco Javier González-Barcala, José Ángel Carretero-Gracia, Manuel Castilla-Martínez, Carolina Cisneros, David Diaz-Pérez, Christian Domingo-Ribas, Eva Martínez-Moragon, Xavier Muñoz, Alicia Padilla-Galo, Miguel Perpiñá-Tordera & Gregorio Soto-Campos. (2022) Documento de consenso de asma grave en adultos. Actualización 2022. Open Respiratory Archives 4:3, pages 100192.
Crossref
Crossref
Serafeim Chrysovalantis Kotoulas, Ioanna Tsiouprou, Eva Fouka, Athanasia Pataka, Despoina Papakosta & Konstantinos Porpodis. (2022) Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma. Journal of Personalized Medicine 12:2, pages 165.
Crossref
Crossref
Brittany Salter, Paige Lacy & Manali Mukherjee. (2022) Biologics in Asthma: A Molecular Perspective to Precision Medicine. Frontiers in Pharmacology 12.
Crossref
Crossref
Alexandrosz Czira, Monica Turner, Amber Martin, David Hinds, Helen Birch, Frances Gardiner & Shiyuan Zhang. (2022) A systematic literature review of burden of illness in adults with uncontrolled moderate/severe asthma. Respiratory Medicine 191, pages 106670.
Crossref
Crossref
Wei Chern Gavin Fong, Adnan Azim, Deborah Knight, Heena Mistry, Anna Freeman, Mae Felongco, Aref Kyyaly, Matthew Harvey, Patrick Dennison, Hongmei Zhang, Peter Howarth, Syed Hasan Arshad & Ramesh J. Kurukulaaratchy. (2021) Real‐world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes. Clinical & Experimental Allergy 51:8, pages 1019-1032.
Crossref
Crossref
Jae-Woo Jung, Hae-Sim Park, Choon-Sik Park, Sang-Heon Cho, Inseon S. Choi, Hee-Bom Moon, Soon Seog Kwon, Ho Joo Yoon, Jung Won Park, Jong-Myung Lee, Dong-Chull Choi & Byoung Whui Choi. (2021) Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma. The Korean Journal of Internal Medicine 36:4, pages 1001-1013.
Crossref
Crossref
Luigino Calzetta, Marina Aiello, Annalisa Frizzelli, Giuseppina Bertorelli, Paola Rogliani & Alfredo Chetta. (2021) Oral Corticosteroids Dependence and Biologic Drugs in Severe Asthma: Myths or Facts? A Systematic Review of Real-World Evidence. International Journal of Molecular Sciences 22:13, pages 7132.
Crossref
Crossref
Jean Bousquet, Marc Humbert, Peter G. Gibson, Konstantinos Kostikas, Xavier Jaumont, Pascal Pfister & Francis Nissen. (2021) Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies. The Journal of Allergy and Clinical Immunology: In Practice 9:7, pages 2702-2714.
Crossref
Crossref
Andriana I. PapaioannouMyrto MplizouKonstantinos PorpodisEvangelia FoukaEleftherios ZervasKonstantinos SamitasMiltiadis MarkatosPetros Bakakos, Spyridon PapirisMina GagaDespoina PapakostaStelios Loukides. (2021) Long-term efficacy and safety of omalizumab in patients with allergic asthma: A real-life study. Allergy and Asthma Proceedings 42:3, pages 235-242.
Crossref
Crossref
Wei-Chang Huang, Pin-Kuei Fu, Ming-Cheng Chan, Chun-Shih Chin, Wen-Nan Huang, Kuo-Lung Lai, Jiun-Long Wang, Wei-Ting Hung, Yi-Da Wu, Chia-Wei Hsieh, Ming-Feng Wu, Yi-Hsing Chen & Jeng-Yuan Hsu. (2021) The Long-Term Effectiveness of Omalizumab in Adult Patients with Severe Allergic Asthma: Continuous Treatment Versus Boosting Treatment. Journal of Clinical Medicine 10:4, pages 707.
Crossref
Crossref
Jordis Trischler, Ivan Bottoli, Reinhold Janocha, Christoph Heusser, Xavier Jaumont, Phil Lowe, Aurelie Gautier, Abhijit Pethe, Ralph Woessner, Hans‐Günter Zerwes & Stefan Zielen. (2021) Ligelizumab treatment for severe asthma: learnings from the clinical development programme. Clinical & Translational Immunology 10:3.
Crossref
Crossref
Jessica Purizaca-Bazán & José Antonio Ortega-Martell. (2020) Bloqueo de inmunoglobulina E en el asma grave. Revista Alergia México 67.
Crossref
Crossref
Giovanni Rolla, Enrico Heffler, Stefano Pizzimenti, Alain Michils & Andrei Malinovschi. (2020) An Emerging Role for Exhaled Nitric Oxide in Guiding Biological Treatment in Severe Asthma. Current Medicinal Chemistry 27:42, pages 7159-7167.
Crossref
Crossref
Petr Vaník, Jakub Novosad, Olga Kirchnerová, Irena Krčmová & Milan Teřl. (2020) Effect of individual allergen sensitization on omalizumab treatment outcomes in patients with severe allergic asthma determined using data from the Czech Anti-IgE Registry. Allergy, Asthma & Clinical Immunology 16:1.
Crossref
Crossref
Levi B. Richards, Job J.M.H. van Bragt, Reim Aarab, Cristina Longo, Anne H. Neerincx, Jaap K. Sont, Els J.M. Weersink, Gert-Jan Braunstahl, Anneke Ten Brinke, Elisabeth H.D. Bel & Anke-Hilse Maitland-van der Zee. (2020) Treatment Eligibility of Real-Life Mepolizumab-Treated Severe Asthma Patients. The Journal of Allergy and Clinical Immunology: In Practice 8:9, pages 2999-3008.e1.
Crossref
Crossref
A.N. Frix, F. Schleich, V. Paulus, F. Guissard, M. Henket & R. Louis. (2020) Effectiveness of omalizumab on patient reported outcomes, lung function, and inflammatory markers in severe allergic asthma. Biochemical Pharmacology 179, pages 113944.
Crossref
Crossref
Nikolaos G. Papadopoulos, Peter Barnes, Giorgio Walter Canonica, Mina Gaga, Liam Heaney, Andrew Menzies‐Gow, Vicky Kritikos & Mark Fitzgerald. (2020) The evolving algorithm of biological selection in severe asthma. Allergy 75:7, pages 1555-1563.
Crossref
Crossref
Francisco Javier Álvarez-Gutiérrez, Marina Blanco-Aparicio, Vicente Plaza, Carolina Cisneros, Juan Luis García-Rivero, Alicia Padilla, Luis Pérez-de Llano, Miguel Perpiñá & Gregorio Soto-Campos. (2020) Documento de consenso de asma grave en adultos. Actualización 2020. Open Respiratory Archives 2:3, pages 158-174.
Crossref
Crossref
Eugene R. Bleecker, Andrew N. Menzies-Gow, David B. Price, Arnaud Bourdin, Stephen Sweet, Amber L. Martin, Marianna Alacqua & Trung N. Tran. (2020) Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management. American Journal of Respiratory and Critical Care Medicine 201:3, pages 276-293.
Crossref
Crossref
Raffaele Campisi, Claudia Crimi, Rossella Intravaia, Simona Strano, Alberto Noto, Maria Pia Foschino, Giuseppe Valenti, Vittorio Viviano, Corrado Pelaia, Luisa Ricciardi, Nicola Scichilone & Nunzio Crimi. (2020) Adherence to omalizumab: A multicenter "real-world" study. World Allergy Organization Journal 13:2, pages 100103.
Crossref
Crossref
Elissa M. Abrams, Heather E. Hoch, Allan B. Becker & Stanley J. Szefler. 2020. Severe Asthma in Children and Adolescents. Severe Asthma in Children and Adolescents
287
312
.
O. M. Kurbacheva & M. A. Galitskaya. (2019) The place of Omalizumab in the treatment of allergic diseases. Medical Council:15, pages 38-49.
Crossref
Crossref
James D. ChambersAri D. PanzerElle F. PopeJennifer S. GraffPeter J. Neumann. (2019) Little Consistency In Evidence Cited By Commercial Plans For Specialty Drug Coverage. Health Affairs 38:11, pages 1882-1886.
Crossref
Crossref
Luis Manuel Entrenas Costa, Francisco Casas-Maldonado, José Gregorio Soto Campos, Alicia Padilla-Galo, Alberto Levy, Francisco Javier Álvarez Gutiérrez, Ana P. Gómez-Bastero Fernández, Concepción Morales-García, Rocío Gallego Domínguez, Gustavo Villegas Sánchez, Luis Mateos Caballero, Antonio Pereira-Vega, Cayo García Polo, Gerardo Pérez Chica & Juan José Martín Villasclaras. (2019) Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study. PharmacoEconomics - Open 3:3, pages 333-342.
Crossref
Crossref
Gilda Varricchi, Giancarlo Marone, Giuseppe Spadaro, Michele Russo, Francescopaolo Granata, Arturo Genovese & Gianni Marone. (2019) Novel Biological Therapies in Severe Asthma: Targeting the Right Trait. Current Medicinal Chemistry 26:16, pages 2801-2822.
Crossref
Crossref
James G. Krings, Mary Clare McGregor, Leonard B. Bacharier & Mario Castro. (2019) Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent. The Journal of Allergy and Clinical Immunology: In Practice 7:5, pages 1379-1392.
Crossref
Crossref
Paraskevi Katsaounou, Roland Buhl, Guy Brusselle, Pascal Pfister, Rafael Martínez, Ulrich Wahn & Jean Bousquet. (2019) Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma. Respiratory Medicine 150, pages 51-62.
Crossref
Crossref
Enrico Heffler, Diego Bagnasco & Giorgio W. Canonica. (2019) Strategies to reduce corticosteroid-related adverse events in asthma. Current Opinion in Allergy & Clinical Immunology 19:1, pages 61-67.
Crossref
Crossref
Giorgio Lorenzo Colombo, Sergio Di Matteo, Chiara Martinotti, Martina Oselin, Maria Chiara Valentino, Giacomo Matteo Bruno, Claudia Pitotti & Francesco Menzella. (2019) Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review. Therapeutic Advances in Respiratory Disease 13, pages 175346661984135.
Crossref
Crossref
Karina Jahnz-Różyk, Joanna Lis, Marta Warchoł & Aleksandra Kucharczyk. (2018) Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in Poland. BMC Pulmonary Medicine 18:1.
Crossref
Crossref
Ihab Mokhtar Weheba, Abeer Mohamed Abdelsayed, Rand Khaled Arnaout, Mohamed Omar Zeitouni, Khalid Fahad Mobaireek, Tahani Bakheet AlHarthi & Abdullah Fahad Mobeireek. (2018) Anti-IgE therapy for asthma: an audit at a tertiary care centre in Saudi Arabia. Annals of Saudi Medicine 38:6, pages 439-444.
Crossref
Crossref
Mitsuru Adachi, Masanari Kozawa, Hajime Yoshisue, Ki Lee Milligan, Makoto Nagasaki, Takayoshi Sasajima, Terumasa Miyamoto & Ken Ohta. (2018) Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan. Respiratory Medicine 141, pages 56-63.
Crossref
Crossref
Doh Hyung KimYoung-Koo Jee. (2018) Is Omalizumab a Problem-Solving Remedy in Severe Asthma?. Allergy, Asthma & Immunology Research 10:2, pages 95.
Crossref
Crossref
Ji-Ho LeeHyun Young LeeChang-Gyu JungGa-Young BanYoo Seob ShinYoung-Min YeDong-Ho NahmHae-Sim Park. (2018) Therapeutic Effect of Omalizumab in Severe Asthma: A Real-World Study in Korea. Allergy, Asthma & Immunology Research 10:2, pages 121.
Crossref
Crossref
Eleftherios Zervas, Konstantinos Samitas, Andriana I. Papaioannou, Petros Bakakos, Stelios Loukides & Mina Gaga. (2018) An algorithmic approach for the treatment of severe uncontrolled asthma. ERJ Open Research 4:1, pages 00125-2017.
Crossref
Crossref
Arzu Yorgancıoğlu, Ferda Öner Erkekol, Dilşad Mungan, Münevver Erdinç, Bilun Gemicioğlu, Zeynep Ferhan Özşeker, Papatya Bayrak Değirmenci , Sibel Naycı, Aykut Çilli, Füsun Erdenen, Cengiz Kırmaz, Dane Ediger, Arzu Didem Yalçın, Suna Büyüköztürk, Sami Öztürk, Mustafa Güleç, Sacide Rana Işık, Ali Fuat Kalyoncu, Özlem Göksel, Ömür Aydın, Yavuz Havlucu, İdilhan Baloğlu Ar & Ahmet Erdoğdu. (2018) Long-Term Omalizumab Treatment: A Multicenter, Real-Life, 5-Year Trial. International Archives of Allergy and Immunology 176:3-4, pages 225-233.
Crossref
Crossref
Mona Al-Ahmad, Nermina Arifhodzic, Jasmina Nurkic, Ahmed Maher, Tito Rodriguez-Bouza, Nasser Al-Ahmed, Ali Sadek & Edin Jusufovic. (2018) "Real-life" Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma. Medical Principles and Practice 27:3, pages 260-266.
Crossref
Crossref
Marc Humbert, William Busse & Nicola A. Hanania. (2018) Controversies and opportunities in severe asthma. Current Opinion in Pulmonary Medicine 24:1, pages 83-93.
Crossref
Crossref
Long Xu, Te Lu, Xiaogang Tao, Dandan Wang, Weiming Liu, Jingsheng Li & Baiyun Liu. (2017) Decompressive craniectomy for malignant middle cerebral artery infarctions: a meta-analysis. Chinese Neurosurgical Journal 3:1.
Crossref
Crossref
Christian Domingo. (2017) Overlapping Effects of New Monoclonal Antibodies for Severe Asthma. Drugs 77:16, pages 1769-1787.
Crossref
Crossref
Danilo Di Bona, Irene Fiorino, Marialuisa Taurino, Flavia Frisenda, Elena Minenna, Carlo Pasculli, Georgios Kourtis, Anna Simona Rucco, Andrea Nico, Marcello Albanesi, Lucia Giliberti, Luciana D'Elia, Maria Filomena Caiaffa & Luigi Macchia. (2017) Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study. Respiratory Medicine 130, pages 55-60.
Crossref
Crossref
Stephen P. Peters & William W. Busse. (2017) New and Anticipated Therapies for Severe Asthma. The Journal of Allergy and Clinical Immunology: In Practice 5:5, pages S15-S24.
Crossref
Crossref
Abdulaziz Alhossan, Christopher S. Lee, Karen MacDonald & Ivo Abraham. (2017) “Real-life” Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis. The Journal of Allergy and Clinical Immunology: In Practice 5:5, pages 1362-1370.e2.
Crossref
Crossref
Adel H. Mansur, Sapna Srivastava, Verity Mitchell, Julie Sullivan & Ismail Kasujee. (2017) Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety. Respiratory Medicine 124, pages 36-43.
Crossref
Crossref
Christian Domingo, Xavier Pomares, Albert Navarro, Núria Rudi, Ana Sogo, Ignacio Dávila & Rosa Mirapeix. (2017) Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study. International Journal of Molecular Sciences 18:3, pages 521.
Crossref
Crossref
Elham Hossny, Luis Caraballo, Thomas Casale, Yehia El-Gamal & Lanny Rosenwasser. (2017) Severe asthma and quality of life. World Allergy Organization Journal 10, pages 28.
Crossref
Crossref
M. Caminati, G. Senna, G. Stefanizzi, R. Bellamoli, S. Longhi, F. Chieco-Bianchi, G. Guarnieri, S. Tognella, M. Olivieri, C. Micheletto, G. Festi, E. Bertocco, M. Mazza, A. Rossi & A. Vianello. (2016) Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience. BMC Pulmonary Medicine 16:1.
Crossref
Crossref
Izabela Kupryś-Lipińska, Paweł Majak, Joanna Molinska & Piotr Kuna. (2016) Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience. BMC Pulmonary Medicine 16:1.
Crossref
Crossref
F. Amat, P. Tallon, A. P. Foray, B. Michaud, N. Lambert, P. Saint-Pierre, L. Chatenoud & J. Just. (2016)
Control of asthma by omalizumab: the role of CD4
+
Foxp3
+
regulatory T cells
. Clinical & Experimental Allergy 46:12, pages 1614-1616.
Crossref
Crossref
Kjell Larsson, Andrew Menzies-Gow & Reynold A. PanettieriJrJr. (2016) Severe Asthma: Challenges and Precision Approaches to Therapy. Pulmonary Therapy 2:2, pages 139-152.
Crossref
Crossref
Andrzej Obojski, Paulina Wełna & Robert Pawłowicz. (2016) Korzyści z leczenia omalizumabem wykraczające poza spodziewane efekty u 38-letniej chorej na ciężką postać astmy alergicznej. Alergologia Polska - Polish Journal of Allergology 3, pages S2-S5.
Crossref
Crossref
María del Carmen Vennera, Antonio Valero, Estefany Uría, Carles Forné & César Picado. (2016) Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain. Clinical Drug Investigation 36:7, pages 567-578.
Crossref
Crossref
I. Abraham, A. Alhossan, C. S. Lee, H. Kutbi & K. MacDonald. (2016) ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy 71:5, pages 593-610.
Crossref
Crossref
Jing LiJian KangChangzheng WangJing YangLinda WangIoannis KottakisMichael HumphriesNanshan Zhong. (2016) Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III Study. Allergy, Asthma & Immunology Research 8:4, pages 319.
Crossref
Crossref
Michael Roth, Feng Zhao, Jun Zhong, Didier Lardinois & Michael Tamm. (2015) Serum IgE Induced Airway Smooth Muscle Cell Remodeling Is Independent of Allergens and Is Prevented by Omalizumab. PLOS ONE 10:9, pages e0136549.
Crossref
Crossref
Marco Caminati, Gianenrico Senna, Massimo Guerriero, Anna Rita Dama, Fulvia Chieco-Bianchi, Giorgia Stefanizzi, Marcello Montagni & Erminia Ridolo. (2015) Omalizumab for severe allergic asthma in clinical trials and real-life studies: What we know and what we should address. Pulmonary Pharmacology & Therapeutics 31, pages 28-35.
Crossref
Crossref
Federica Novelli, Manuela Latorre, Letizia Vergura, Maria Filomena Caiaffa, Gianna Camiciottoli, Gabriella Guarnieri, Andrea Matucci, Luigi Macchia, Andrea Vianello, Alessandra Vultaggio, Alessandro Celi, Mario Cazzola & Pierluigi Paggiaro. (2015) Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy. Pulmonary Pharmacology & Therapeutics 31, pages 123-129.
Crossref
Crossref
Binita Kane, Stephen J Fowler & Rob Niven. (2014) Refractory asthma – beyond step 5, the role of new and emerging adjuvant therapies. Chronic Respiratory Disease 12:1, pages 69-77.
Crossref
Crossref
Caroline Gouder, Lorna Marie West & Stephen Montefort. (2014) The real-life clinical effects of 52 weeks of omalizumab therapy for severe persistent allergic asthma. International Journal of Clinical Pharmacy 37:1, pages 36-43.
Crossref
Crossref
Susanne Radonjic-HoesliPeter Valent, Amy D. Klion, Michael E. Wechsler & Hans-Uwe Simon. (2015) Novel Targeted Therapies for Eosinophil-Associated Diseases and Allergy. Annual Review of Pharmacology and Toxicology 55:1, pages 633-656.
Crossref
Crossref
Naresh Singh Redhu & Abdelilah S Gounni. (2015) IgE regulates airway smooth muscle phenotype: Future perspectives in allergic asthma. World Journal of Immunology 6:3, pages 126.
Crossref
Crossref
Marco Caminati, Gianenrico Senna, Fulvia Chieco Bianchi, Maria Rita Marchi, Andrea Vianello, Claudio Micheletto, Carlo Pomari, Silvia Tognella, Francesca Savoia, Valentina Mirisola & Andrea Rossi. (2014) Omalizumab management beyond clinical trials: The added value of a network model. Pulmonary Pharmacology & Therapeutics 29:1, pages 74-79.
Crossref
Crossref
Claus Kroegel & Martin Foerster. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
1775
1824
.
S. Saturni, F. Bellini, F. Braido, P. Paggiaro, A. Sanduzzi, N. Scichilone, P.A. Santus, L. Morandi & A. Papi. (2014) Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view.. Pulmonary Pharmacology & Therapeutics 27:2, pages 129-138.
Crossref
Crossref
Nathan Hambly & Parameswaran Nair. (2014) Monoclonal antibodies for the treatment of refractory asthma. Current Opinion in Pulmonary Medicine 20:1, pages 87-94.
Crossref
Crossref
Kate McKeage. (2013) Omalizumab: A Review of its Use in Patients with Severe Persistent Allergic Asthma. Drugs 73:11, pages 1197-1212.
Crossref
Crossref